IBIO Stock Price: iBio Inc. edges slightly lower after three consecutive days of big gains

NYSEAMERICAN:IBIO falls by 0.50% on Thursday after three straight days of gains at the start of the week.
iBIO has finally decided on IBIO-201 as its coronavirus vaccine of choice.
The entire COVID-19 biotech industry gained this week after AstraZeneca’s leading vaccine trial was halted.

Stocks Reporter FXStreet

NYSEAMERICAN:IBIO finally fell on Thursday alongside broader markets as the fallout from AstraZeneca halting its coronavirus vaccine study finally levelled off. iBIO has been a popular biotech penny stock amongst bargain investors that are targeting these micro-cap firms as potential industry disruptors. The stock has performed admirably thus far this year up 212.50% during the past 52-weeks – although shares are down over 70% from its 52-week highs of $7.45.

IBIO is more than just a coronavirus vaccine candidate though and investors know that the New York-based company has some more aces up its sleeve. Even if IBIO-201 is not chosen as the one the vaccines used to combat COVID-19, iBIO Inc. is well-positioned to be a global manufacturer of vaccine components with its FastPharming facility located in Bryan, Texas. The world is going to need upwards of 7 billion vaccines at some point and it may inevitably be a combination of biotech firms that band together to conquer the novel coronavirus.

IBIO Stock News

iBIO also has its hands in other sectors as it is developing IBIO-100 as well, which is a fusion protein for the treatment of fibrotic diseases. The recent selloff leading up to the AstraZeneca news has battered the stock down to levels where bargain investors should once again take notice. The race for the COVID-19 vaccine is wide open as other firms continue to fail and other companies have the chance to step up to the plate. While ultimately IBIO may not be the vaccine that is chosen, it certainly has a chance of carving out a role in the manufacturing of vaccines for global use.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

EUR/USD looks to regain the 200-day SMA

EUR/USD regains some balance and trade just above 1.1600 the figure ahead of the opening bell in Asia. The pair initially dipped to the 1.1530 zone for the first time since November, always following the stronger US Dollar and the marked flight-to-safety in the context of the ongoing Middle East crisis

GBP/USD attacks 1.3300, refreshing three-month lows

GBP/USD is deep in the red near 1.3300, accelerating its downside to renew three-month lows in European trading on Tuesday. The ongoing escalation in the Iran war, combined with rising Oil prices, weighs negatively on the higher-yielding Pound Sterling as the US Dollar capitalizes on increased haven demand.

Gold bounces off lows, back above $5,100

Gold remains on the defensive, eroding part of the recent multi-day advance and managing to trade back above the $5,100 mark per troy ounce on Tuesday. The precious metal initially dropped just below the critical $5,000 threshold on the back of the persistent strength of the Greenback, higher US Treasury yields across the curve and investors' repricing of Fed rate cuts.